KalVista price target lowered to $20 from $24 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on KalVista to $20 from $24 and keeps a Buy rating on the shares. The analyst believes sebetralstat is well positioned for approval and is backed by the positive Phase 3 KONFIDENT trial data.